Navigation Links
EntreMed ENMD-2076 Phase 2 Data to Be Presented at ASCO Annual Meeting
Date:5/19/2011

ROCKVILLE, Md., May 19, 2011 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the presentation of clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.  The data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 3 - 7, 2011 in Chicago, Illinois.

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO)-

Gynecologic Cancer Track: Poster SessionFriday, June 3, 2011 – 2:00 p.m. - 6:00 p.m. (CDT) Abstract No.: 5021Title: A Phase 2 Study of ENMD-2076 in platinum-resistant ovarian cancer Poster Board: 10, Location: E450aDiscussion SessionFriday, June 3, 2011 – 5:00 p.m. - 6:00 p.m. (CDT)Location: E354bAbout ENMD-2076ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrated significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. While ENMD-2076 is currently in a Phase 2 trial in ovarian cancer, preclinical and clinical activities are ongoing in assessing the compound's applicability in other forms of cancer.

About EntreMedEntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.  ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including  the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the failure to consummate a transaction to monetize the royalty stream for any reason, including our inability to obtain the required third-party consents; declines in actual sales of Thalomid® resulting in reduced revenues; risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks). 

CONTACT:
Ginny Dunn
Associate Director, Corporate Communications & Investor Relations
EntreMed, Inc.
240.864.2643


'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)...  Sysmex America, Inc., a leading provider of ... well as middleware information systems technology, today announced ... assurance easier and more risk free than manual ... the innovation that it delivers to the laboratory. ... processes to a new level with automated, continuous ...
(Date:7/11/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... (FDA) has agreed to schedule an End-of-Phase II meeting ... of its oral insulin capsule ORMD-0801 in the treatment ... primary and secondary endpoints by indicating a statistically significant ...
(Date:7/10/2017)... 2017 The Institute for In Vitro Sciences ... recipient of a VITROCELL® inhalation exposure system thanks to ... The device, which is designed to replace animals in ... cells to airborne test materials in an environment that ... system for testing combustible tobacco products, as well as ...
Breaking Medicine Technology:
(Date:7/26/2017)... ... ... Capillus, LLC has announced the redesign of their FDA-cleared low-level laser (light) therapy ... more comfortable, adaptable fit and is available for purchase immediately. , Carlos Piña, ... caps intended to improve both user experience and hair regrowth. , “Our customers ...
(Date:7/26/2017)... , ... July 26, 2017 , ... It may be ... often not accessible to people in the third world. Diseases that many developed countries ... poor children who don't have access to vaccines. , On an upcoming segment of ...
(Date:7/26/2017)... ... July 26, 2017 , ... Team Type 1 Foundation, a nonprofit organization pursuing ... by diabetes, is excited to announce the 106 college athletes with type 1 diabetes ... in 2005, the Team Type 1 Foundation has bestowed a total of 271 college ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... The Amnesty ... p.m. at Charles Johnson Park at 3313 Bernstein Park Drive in Monroe (adjacent to ... Rally is to help reduce gun violence throughout Monroe. Citizens can turn in ...
(Date:7/25/2017)... ... 25, 2017 , ... Summers in Palm Springs sizzle, but there are ways ... gourmet ice cream, sparkling pools, and mile-high fun. , At Arrive's Ice Cream and ... other must-have knick knacks. Ice cream and sorbet flavors rotate, but the classics are ...
Breaking Medicine News(10 mins):